| Execution period | Valid up to April 29, 2027 |
|---|
NSE filing, NSE: JAYBEE. Summary written from the filing by ALFA Finder's alert engine.
Jay Bee Laminations Ltd: key numbers
- Share price
- ₹82.50
- Market cap
- ₹186.2 Cr
- Revenue (annual)
- ₹548.0 Cr
- Net profit (annual)
- ₹18.26 Cr
- P/E (TTM)
- 10.2×Sector 52.8×
- Promoter holding
- 70.61%
- FII holding
- 0.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jay Bee Laminations Ltd
All →Jay Bee Laminations Annual General Meeting
Jay Bee Laminations held its 38th AGM on September 26, 2026, via video conferencing. Shareholders transacted ordinary and special business, including borrowing and charge approvals.
Jay Bee Laminations Annual General Meeting
Jay Bee Laminations Limited has scheduled its 38th Annual General Meeting for September 26, 2026, to transact ordinary and special business, including borrowing power approvals.
Jay Bee Laminations Board Meeting Outcome
Jay Bee Laminations Limited's board approved the appointment of secretarial, internal, and cost auditors for FY 2026-27. It also approved the notice for its 38th AGM.
Jay Bee Laminations Management Change
Mr. Atul Ladha resigned as Independent Director of Jay Bee Laminations. The resignation is effective from June 26, 2026.
Jay Bee Laminations Management Change
Jay Bee Laminations redesigned Mrs. Sunita Aggarwal from Executive Director to Non-Executive Non-Independent Director. Effective May 26, 2026, the move adjusts the board's leadership structure.
Jay Bee Laminations Board Meeting Outcome
Jay Bee Laminations approved redesignating Mrs. Sunita Aggarwal from Executive to Non-Executive Non-Independent Director. The change aligns with her evolving strategic guidance and advisory role.
Other regulatory approval announcements
All →Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.